NASDAQ:TVTX Travere Therapeutics (TVTX) Stock Price, News & Analysis $59.44 -1.18 (-1.95%) Closing price 04:00 PM EasternExtended Trading$59.45 +0.01 (+0.02%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Travere Therapeutics Stock (NASDAQ:TVTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Travere Therapeutics alerts:Sign Up Key Stats Today's Range$59.05▼$60.8950-Day Range$54.98▼$67.5252-Week Range$22.06▼$68.73Volume1.21 million shsAverage Volume1.47 million shsMarket Capitalization$5.60 billionP/E RatioN/ADividend YieldN/APrice Target$69.50Consensus RatingModerate Buy Company Overview Travere Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for rare kidney and immune-mediated diseases. The company’s work is centered on conditions with significant unmet medical needs, including diseases that can lead to progressive kidney damage and kidney failure. Travere’s principal commercial product is FILSPARI (sparsentan), an oral therapy for adults with primary immunoglobulin A nephropathy, or IgA nephropathy, who are at risk of disease progression. FILSPARI is designed to reduce proteinuria, a key marker of kidney injury, and received U.S. regulatory approval for this indication. The company continues to study sparsentan and other potential therapies for kidney disorders. The company was founded in 2008 as Retrophin and adopted the name Travere Therapeutics in 2020. Based in San Diego, California, Travere serves patients primarily through its U.S. commercial operations and pursues international opportunities through regulatory submissions and strategic partnerships. Eric Dube, Ph.D., serves as president and chief executive officer.AI Generated. May Contain Errors. Read More Travere Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks38th Percentile Overall ScoreTVTX MarketRank™: Travere Therapeutics scored higher than 38% of companies evaluated by MarketBeat, and ranked 722nd out of 908 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingTravere Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 10 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialTravere Therapeutics has a consensus price target of $69.50, representing about 16.9% upside from its current price of $59.44.Amount of Analyst CoverageTravere Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Travere Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Travere Therapeutics are expected to grow in the coming year, from ($0.54) to $2.63 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Travere Therapeutics is -129.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Travere Therapeutics is -129.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTravere Therapeutics has a P/B Ratio of 46.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Travere Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.38% of the float of Travere Therapeutics has been sold short.Short Interest Ratio / Days to CoverTravere Therapeutics has a short interest ratio ("days to cover") of 10.38, which indicates bearish sentiment.Change versus previous monthShort interest in Travere Therapeutics has recently increased by 7.92%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTravere Therapeutics does not currently pay a dividend.Dividend GrowthTravere Therapeutics does not have a long track record of dividend growth. News and Social Media2.3 / 5News Sentiment0.69 News SentimentTravere Therapeutics has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Travere Therapeutics this week, compared to 6 articles on an average week.Search InterestOnly 1 people have searched for TVTX on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Travere Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Travere Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $66,336,443.00 in company stock.Percentage Held by Insiders4.44% of the stock of Travere Therapeutics is held by insiders.Percentage Held by InstitutionsTravere Therapeutics has minimal institutional ownership at this time.Read more about Travere Therapeutics' insider trading history. Receive TVTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Travere Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TVTX Stock News HeadlinesTravere Therapeutics (NASDAQ:TVTX) Earns "Outperform" Rating from WedbushSeptember 24 at 1:42 AM | americanbankingnews.comTravere Therapeutics (TVTX) Sets CEO Handover For December 2026September 22 at 11:03 PM | finance.yahoo.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.September 25 at 1:00 AM | Porter & Company (Ad)Travere Therapeutics (TVTX) Stock May Trade Above Fair Value TodaySeptember 22 at 1:02 PM | finance.yahoo.comTravere Therapeutics, Inc. Announces CEO Changes, Effective December 1, 2026September 21, 2026 | marketscreener.comMTravere Therapeutics Announces Planned Chief Executive Officer TransitionSeptember 21, 2026 | businesswire.comTravere Therapeutics (NASDAQ:TVTX) CAO Sandra Calvin Sells 5,375 SharesSeptember 18, 2026 | insidertrades.comTravere Therapeutics (NASDAQ:TVTX) Director Sells $1,346,200.00 in StockSeptember 12, 2026 | insidertrades.comSee More Headlines TVTX Stock Analysis - Frequently Asked Questions How have TVTX shares performed this year? Travere Therapeutics' stock was trading at $38.21 at the beginning of the year. Since then, TVTX shares have increased by 55.6% and is now trading at $59.44. How were Travere Therapeutics' earnings last quarter? Travere Therapeutics, Inc. (NASDAQ:TVTX) issued its earnings results on Tuesday, August, 4th. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.03. The firm's revenue for the quarter was up 48.2% on a year-over-year basis. Read the conference call transcript. Who are Travere Therapeutics' major shareholders? Top institutional investors of Travere Therapeutics include Jupiter Topco LLC (12.01%), Bank of America Corp DE (4.85%), Wellington Management Group LLP (1.63%) and Legal & General Group Plc (0.50%). Insiders that own company stock include Eric M Dube, Peter Heerma, Elizabeth E Reed, Jula Inrig, William E Rote, Jeffrey A Meckler, Christopher R Cline, Gary A Lyons, Timothy Coughlin, Sandra Calvin and Roy D Baynes. View institutional ownership trends. How do I buy shares of Travere Therapeutics? Shares of TVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Travere Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Travere Therapeutics investors own include Meta Platforms (META), NVIDIA (NVDA), Home Depot (HD), Netflix (NFLX), Advanced Micro Devices (AMD) and Cisco Systems (CSCO). Company Calendar Last Earnings8/04/2026Today9/25/2026Next Earnings (Estimated)10/29/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (5m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 TVTX's financial health is in the Green zone, according to TradeSmith. TVTX has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:TVTX CIK1438533 Webwww.travere.com Phone(888) 969-7879Fax302-645-1280Employees497Year Founded2011Price Target and Rating Average Price Target for Travere Therapeutics$69.50 High Price Target$89.00 Low Price Target$41.00 Potential Upside/Downside+16.9%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($0.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$25.55 million Net Margins-7.35% Pretax Margin-11.34% Return on Equity-55.15% Return on Assets-6.88% Debt Debt-to-Equity Ratio24.58 Current Ratio4.05 Quick Ratio3.99 Sales & Book Value Annual Sales$490.73 million Price / Sales11.42 Cash Flow$0.36 per share Price / Cash Flow167.40 Book Value$1.28 per share Price / Book46.44Miscellaneous Outstanding Shares94,260,000Free Float90,076,000Market Cap$5.60 billion OptionableOptionable Beta1.05 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:TVTX) was last updated on 9/25/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Travere Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
